ziftomenib,revumenib
kura oncology,syndax pharma
['ziftomenib', 'kura ', '$sndx', '$kura']
$kura effectively admitting that ziftomenib monorx is limited to npm1m disease. little activity plus differentiation syndrome in kmt2ar limits this use to future combos. meanwhile, $sndx problem is qtc across all populations #ash22
Journalist at Evaluate Vantage. Proudly blocked by @JohnCendpts. Interested in: oncology, immunology. Not interested in: what stock you bought today.